Microbot Medical Commenced its First Step in the Anticipated Regulatory Process for its LIBERTY Robotic System

GLP Pre-Clinical Trial Commenced at a Leading Research Institute by Global Leaders in the Endovascular Space

HINGHAM, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) announces the commencement of its GLP Pre-Clinical Trial for the LIBERTY Robotic System at a world-class MedTech research laboratory. The study is being conducted by top Key Opinion Leaders (KOLs).

“This much anticipated and important milestone represents the first step in our path to achieve regulatory approvals as we aim to transform the world of surgical robotics in general, and specifically in the endovascular space,” commented Harel Gadot, Chairman, CEO and President. “We believe, based on the multiple successful feasibility studies performed to date, that we will be able to successfully meet the study’s endpoints, allowing us to continue progressing toward various regulatory approvals.”